deltatrials
Completed PHASE3 NCT00000637

A Randomized Comparative Trial of Zidovudine (AZT) Versus 2',3'-Dideoxyinosine (ddI) Versus AZT Plus ddI in Symptomatic HIV-Infected Children

Sponsor: Bristol-Myers Squibb

Conditions HIV Infections
Interventions Didanosine Zidovudine
Updated 7 times since 2017 Last updated: Oct 26, 2021 Completion: Sep 30, 1996

A PHASE3 clinical study on HIV Infections, this trial is completed. The trial is conducted by Bristol-Myers Squibb and has accumulated 7 data snapshots since 2026. Infectious disease trials contribute critical data for public health response and treatment development.

Change History

7 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE3

  4. Dec 2021 — Jul 2024 [monthly]

    Completed PHASE3

  5. Jan 2021 — Dec 2021 [monthly]

    Completed PHASE3

▶ Show 2 earlier versions

  1. Jun 2018 — Jan 2021 [monthly]

    Completed PHASE3

  2. Jan 2017 — Jun 2018 [monthly]

    Completed PHASE3

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Bristol-Myers Squibb
  • Glaxo Wellcome
  • National Institute of Allergy and Infectious Diseases (NIAID)
Data source: National Institute of Allergy and Infectious Diseases (NIAID)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Albany, United States, Atlanta, United States, Baltimore, United States, Bayamón, Puerto Rico, Birmingham, United States, Boston, United States, Brooklyn, United States, Buffalo, United States, Chapel Hill, United States, Charleston, United States and 41 more location s